( -Second Closure of Multi-Center Trial i...)The International Myeloma Foundation Reports Positive Shift In,Treatment Paradigm For Patients,Health

NORTH HOLLYWOOD, Calif., May 15, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said that for the second time in four weeks a multi-center myeloma trial using REVLIMID(R) has demonstrated positive findings and therefore has been halted early. As a result medical experts are backing the use of new, less toxic and more tolerable treatments for multiple myeloma, the second most common of the blood cancers in the United States.

    -- In April, the Eastern Cooperative Oncology Group (ECOG) stopped the use

       of high dose dexamethasone, a steroid commonly used when treating

       patients with REVLIMID, (lenalidomide) an oral medication from Celgene.

       Based on the findings, the data safety monitoring committee recommended

       all patients in the study be moved to a regimen of REVLIMID with low-

       dose dexamethasone, which demonstrated improved survival and was better

       tolerated.

    -- Now based on these findings and early analysis of its own data the

       Southwest Oncology Group (SWOG), the largest of the NIH sponsored

       multi-center cooperative group, has brought its trial of high dose

       dexamethasone versus Revlimid plus high dose dexamethasone to an early

       close and also recommended patients be transitioned to a REVLIMID/LDD

       regimen.

    -- Based on these findings, The International Myeloma Foundation's US

       MYELOMA FORUM, a committee of the nation's leading myeloma experts, is

       considering the first large, inter-group trial for newly-diagnosed

       patients using novel agents (either REVLIMID with low-dose

       dexamethasone  or REVLIMD plus other agents such as VELCADE(R) with

       low-dose dexameth
'"/>




Page: 1 2 3 
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their
NCE’s SUVN-502 and SUVN-507at International Brain Research
Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily
Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global
Medical Meeting in Greece Demonstrates Improved Survival for a Wide
Range of Myeloma Patients